Your session is about to expire
← Back to Search
Behavioural Intervention
Ketogenic Diet vs Mixed Diet for Heart Failure
N/A
Recruiting
Led By Yuchi Han, MD, MMSc
Research Sponsored by Ohio State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥ 18 years old and ≤ 80 years old & willingness to be randomized to either diet
Be older than 18 years old
Must not have
History of diabetic ketoacidosis
Women who are pregnant, current breast-feeding, or have intention to become pregnant while in the study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 weeks, and end of the study (26 weeks)
Awards & highlights
No Placebo-Only Group
Summary
This trial is comparing a ketogenic diet and a low-fat diet in people with heart failure and diabetes or related conditions. The goal is to see which diet improves exercise tolerance better. The ketogenic diet helps the body use fat for energy, while the low-fat diet focuses on reducing fat intake.
Who is the study for?
Adults aged 18-80 with heart failure, normal heart pumping function, and either diabetes, pre-diabetes, metabolic syndrome or obesity (BMI between 25-50) can join. They must have stable health for the past 3 months and be able to exercise on a treadmill. People with severe kidney disease, Type I diabetes, recent heart attacks or certain other serious health conditions cannot participate.
What is being tested?
The trial is testing how well two diets - a low carbohydrate ketogenic diet and a low-fat mixed diet - help people with heart failure improve their ability to exercise. Participants will be randomly assigned to one of these diets to see which is more effective.
What are the potential side effects?
Potential side effects from the ketogenic diet may include nutritional deficiencies, constipation or diarrhea due to high fat intake. The mixed diet could lead to unbalanced nutrition if not properly followed. Both diets require strict adherence that might affect lifestyle.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 80 years old and open to trying a new diet.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had diabetic ketoacidosis in the past.
Select...
I am not pregnant, breastfeeding, nor plan to become pregnant during the study.
Select...
My kidney function is severely reduced.
Select...
I have had or will have heart surgery within a month.
Select...
I have had a heart transplant or am on the waiting list for one.
Select...
I needed strong heart failure medication or mechanical support in the last week.
Select...
I have not had, nor am I scheduled for, major surgery within 3 months.
Select...
I have Type I diabetes.
Select...
I need oxygen therapy for a lung condition.
Select...
I have a specific heart condition like amyloidosis or muscular dystrophy affecting my heart.
Select...
I have had severe low potassium levels below 3.0 mg/dL.
Select...
I have ongoing irregular heartbeats.
Select...
I have severe heart valve issues likely needing surgery soon.
Select...
I have had heart rhythm problems that were not controlled or treated.
Select...
I do not have heart conditions that could worsen my health unexpectedly.
Select...
My liver tests are more than three times the normal limit.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 6 weeks, and end of the study (26 weeks)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 weeks, and end of the study (26 weeks)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in maximal exercise performance
Secondary study objectives
B-natriuretic peptide (BNP)
Change Stroke Volume(mL) via cardiovascular magnetic resonance imaging (CMR)
Change in Cardiac Output (L/min) via cardiovascular magnetic resonance imaging (CMR) .
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Low-fat mixed DietExperimental Treatment1 Intervention
This arm will be provided food consisting of \~25% fat, and the remaining calories from carbohydrate (\~55% after accounting for protein at \~20%).
Group II: Ketogenic DietExperimental Treatment1 Intervention
This arm will be provided food to induce a state of nutritional ketosis in each person as defined as blood Beta-hydroxybutyrate (3-OHB) ≥0.5 millimoles (mM), which will require most participants to consume \<50 g/day carbohydrate and 1.5g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketogenic diet
2020
Completed Early Phase 1
~720
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for heart failure, such as the ketogenic diet and low-fat diet, work through different metabolic mechanisms. The ketogenic diet induces ketosis, promoting fat utilization over glucose, which may enhance cardiac energy efficiency and reduce harmful lipid accumulation in the heart.
This can improve exercise tolerance and provide cardio-protective benefits. Conversely, a low-fat diet reduces fat intake and increases carbohydrate consumption, aiding in weight management and improving metabolic risk factors.
These dietary interventions are crucial for heart failure patients as they target metabolic pathways to improve heart function and overall health.
Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet.Low carbohydrate ketogenic diet enhances cardiac tolerance to global ischaemia.
Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet.Low carbohydrate ketogenic diet enhances cardiac tolerance to global ischaemia.
Find a Location
Who is running the clinical trial?
Ohio State UniversityLead Sponsor
871 Previous Clinical Trials
655,642 Total Patients Enrolled
17 Trials studying Heart Failure
52,655 Patients Enrolled for Heart Failure
United States Department of DefenseFED
916 Previous Clinical Trials
334,627 Total Patients Enrolled
1 Trials studying Heart Failure
81 Patients Enrolled for Heart Failure
Yuchi Han, MD, MMScPrincipal InvestigatorOhio State University
1 Previous Clinical Trials
30 Total Patients Enrolled
1 Trials studying Heart Failure
30 Patients Enrolled for Heart Failure